Healthcare
SymBio Pharmaceuticals Limited(SYMQY)
Live Price
Offline$0.5579
+0.00% today
1Y Change
-38.01%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $4.52B
- Revenue Growth
- -44.1%
- EPS Growth
- -18.6%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SymBio Pharmaceuticals Limited (SYMQY) is a Healthcare stock with a market cap of $4.52B and listed on OTC. The stock last traded around $0.56 and down 38.0% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -44.1%, EPS growth of -18.6%, a dividend yield of 0.0%. What stands out right now is revenue -44.1%, EPS -18.6%, free cash flow -38.5% with operating margin -339.6% and ROIC -136.2%. Valuation is more restrained than many high-expectation growth names at price/sales 3.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SYMQY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-44.1% vs +7.6% peer median
Operating Margin
Below sector median
-339.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -44.1% and EPS is at -18.6%, with operating margin around -339.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.4% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Feb 5, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Oct 30, 2025 | โ | +0.0% | -25.3% | -25.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYMQY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SYMQY Max Drawdown
-53.12%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SYMQY and SPY.
Company Overview
SymBio Pharmaceuticals Limited
Other OTC
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.
- Leadership
- Fuminori Yoshida
- IPO Date
- Aug 5, 2016
- Employees
- 108
- Street Address
- Toranomon 30 Mori Building
- Mailing
- Tokyo, 105-0001
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 5472 1125
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.5
- Price/Book
- 3.6
Growth
- Revenue
- -44.1%
- EPS
- -18.6%
- Free Cash Flow
- -38.5%
Profitability
- Gross Margin
- 72.4%
- Operating Margin
- -339.6%
- Net Margin
- -365.3%
- ROE
- -219.9%
- ROIC
- -136.2%
Balance Sheet
- Debt/Equity
- 1.56
- Current Ratio
- 2.96
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.